JP2008519001A - アリールピリミジル化合物、それらを含む医薬組成物、抗菌剤としてのそれらの使用 - Google Patents

アリールピリミジル化合物、それらを含む医薬組成物、抗菌剤としてのそれらの使用 Download PDF

Info

Publication number
JP2008519001A
JP2008519001A JP2007539555A JP2007539555A JP2008519001A JP 2008519001 A JP2008519001 A JP 2008519001A JP 2007539555 A JP2007539555 A JP 2007539555A JP 2007539555 A JP2007539555 A JP 2007539555A JP 2008519001 A JP2008519001 A JP 2008519001A
Authority
JP
Japan
Prior art keywords
arom
group
alkyl
formula
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007539555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519001A5 (enExample
Inventor
ムニエ−レーマン，エレーヌ
ドゥゲ，ドミニク
ラベッセ，ジル
ポシェ，シルヴィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2008519001A publication Critical patent/JP2008519001A/ja
Publication of JP2008519001A5 publication Critical patent/JP2008519001A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007539555A 2004-11-05 2005-11-04 アリールピリミジル化合物、それらを含む医薬組成物、抗菌剤としてのそれらの使用 Withdrawn JP2008519001A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292629A EP1655288A1 (en) 2004-11-05 2004-11-05 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
PCT/EP2005/012346 WO2006048336A2 (en) 2004-11-05 2005-11-04 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents

Publications (2)

Publication Number Publication Date
JP2008519001A true JP2008519001A (ja) 2008-06-05
JP2008519001A5 JP2008519001A5 (enExample) 2008-12-25

Family

ID=34931507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539555A Withdrawn JP2008519001A (ja) 2004-11-05 2005-11-04 アリールピリミジル化合物、それらを含む医薬組成物、抗菌剤としてのそれらの使用

Country Status (7)

Country Link
US (1) US20080096907A1 (enExample)
EP (2) EP1655288A1 (enExample)
JP (1) JP2008519001A (enExample)
CN (1) CN101098860A (enExample)
BR (1) BRPI0517646A (enExample)
CA (1) CA2586073A1 (enExample)
WO (1) WO2006048336A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512524A (ja) * 2016-03-22 2019-05-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI445696B (zh) * 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的ｄｎａ修復毒性
RU2475482C1 (ru) * 2012-01-13 2013-02-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" Комплексное соединение 5-гидрокси-6-метилурацила с сукцинатом натрия и способ его получения
US20220041627A1 (en) * 2018-12-04 2022-02-10 University Of Maryland, Baltimore Prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1959705A1 (de) * 1969-11-28 1971-06-03 Bayer Ag Verfahren zur Herstellung von Uracilderivaten
JPH08325238A (ja) * 1995-05-30 1996-12-10 Asahi Glass Co Ltd ５−トリフルオロメチルウラシル誘導体およびその製造方法
ATE201016T1 (de) * 1995-06-09 2001-05-15 Hoffmann La Roche Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
EP1255738B1 (en) * 2000-01-25 2012-03-07 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
JP4542311B2 (ja) * 2001-01-29 2010-09-15 バイオ−ラッド ラボラトリーズ インコーポレイテッド 核酸誘導体
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512524A (ja) * 2016-03-22 2019-05-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規使用

Also Published As

Publication number Publication date
BRPI0517646A (pt) 2008-10-14
US20080096907A1 (en) 2008-04-24
CA2586073A1 (en) 2006-05-11
CN101098860A (zh) 2008-01-02
EP1814867A2 (en) 2007-08-08
WO2006048336B1 (en) 2006-11-09
WO2006048336A2 (en) 2006-05-11
WO2006048336A3 (en) 2006-10-12
EP1655288A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
Gasse et al. Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: Synthesis and in vitro anti-mycobacterial activity
Wigerinck et al. 5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication
DE69511253T2 (de) Wasserlösliche 3-arylidene-2-oxindole derivate als tyrosine kinase inhibitoren
JP5400032B2 (ja) ベンズイミダゾール及びその医薬組成物
Balzarini et al. Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine
EP0484071A2 (en) Synergism of HIV reverse transcriptase inhibitors
WO2003006670A2 (en) 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
JPH11263789A (ja) プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
JP2008519001A (ja) アリールピリミジル化合物、それらを含む医薬組成物、抗菌剤としてのそれらの使用
CA2955379A1 (en) Methods and compositions for treating hiv-related disorders
JP2011111433A (ja) ウレイド構造を有するウラシル化合物又はその塩
CN111087408B (zh) 一种大环结构的idh2突变体抑制剂及其医药用途
US12209090B2 (en) 3,6-disubstituted-2-pyridinaldoxime scaffolds
CN109369623A (zh) 一种取代1,2,3三氮唑类二芳基嘧啶衍生物及其制备方法与应用
Kelley et al. Pyrimidine acyclic nucleosides. 5-Substituted 1-[(2-aminoethoxy) methyl] uracils as candidate antivirals
WO1996040680A1 (en) Novel non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (garft)
JPH0629264B2 (ja) ２‐アミノ‐５‐ヒドロキシ‐４‐ピリミドン
CA2980221C (en) Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof
JP2006527211A (ja) ホルモン感受性リパーゼの阻害剤として使用するための１−アリール−４−（アリールオキシカルボニル）−ピペラジン誘導体
EP3820847B1 (en) Improved compounds for myc inhibition
HK1091820A (en) Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
EP3749306B1 (en) Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same
PT2307375E (pt) Compostos da fenantrenona, composições e métodos
TWI687418B (zh) 唑苯衍生物之結晶
CN110078724A (zh) 一种含吲哚丙酸罗丹宁结构的ptp1b抑制剂及其制备和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081027

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110823